Inflammatory Breast Cancer
📧 Sign up to get email alerts when something new happens for Inflammatory Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating neratinib and paclitaxel with or without pertuzumab and trastuzumab before combination chemotherapy in metastatic…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Onvansertib + Paclitaxel In TNBC [Phase 1, Phase 2]
This document reports an ongoing Phase 1/2 clinical trial evaluating the combination of onvansertib with paclitaxel in patients with triple-…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy [Phase 2]
Phase 2 trial evaluating pembrolizumab in hormone receptor-positive, localized inflammatory breast cancer patients on hormone therapy who di…
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer [Phase 3]
A Phase 3 trial update reports results for patient preference regarding home administration of a subcutaneous fixed-dose combination of pert…
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating a combination of atezolizumab, cobimetinib, and eribulin in chemotherapy-resistant metastatic inflammatory…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-02Clinical Trial Update: Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy [Phase 2]
This Phase 2 clinical trial update evaluates pembrolizumab in patients with stage IV inflammatory breast cancer or triple-negative breast ca…
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer [Phase 1, Phase 2]
This document reports a Phase 1/2 trial of grapiprant plus eribulin for metastatic inflammatory breast cancer, which was terminated and whos…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test [Phase 1, Phase 2]
A Phase Ib/II trial evaluating neratinib plus capmatinib in metastatic breast cancer and inflammatory breast cancer with abnormal HER-family…
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating an omega-3 fatty acid-based anti-cancer therapy in patients with metastatic triple-negative inflammato…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer [Phase 2]
Phase 2 trial evaluating ruxolitinib in combination with preoperative chemotherapy for triple-negative inflammatory breast cancer; the study…
-
CLINICAL_TRIALS trial_result · 2023-08-29Clinical Trial Update: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients [Phase 2, Phase 3]
A Phase 2/Phase 3 trial investigates weekly paclitaxel and cisplatin for various breast cancer subtypes, including hormone receptor positive…
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer [Phase 2]
Phase 2 trial update of pertuzumab plus trastuzumab and nab-paclitaxel (albumin-stabilized nanoparticle paclitaxel) for HER2-positive advanc…
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer [Phase 2]
Phase 2 trial evaluating accelerated radiation therapy after surgery for breast cancer; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial exploring pre-surgical treatment with carboplatin and an albumin-stabilized nanoparticle formulation of paclitaxel in patien…
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery [Phase 2]
Phase 2 clinical trial of talimogene laherparepvec for recurrent breast cancer that cannot be removed surgically has been terminated; result…
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer [Phase 2]
Phase 2 trial evaluating eribulin followed by the AC chemotherapy regimen as preoperative therapy for HER2-negative inflammatory breast canc…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer [Phase 2]
Phase 2 trial evaluating panitumumab with nab-paclitaxel and carboplatin for HER2-negative inflammatory breast cancer has completed recruitm…
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) [Phase 2]
Phase 2 trial evaluating nivolumab in combination with chemotherapy as neoadjuvant treatment for inflammatory breast cancer has completed wi…
-
CLINICAL_TRIALS trial_result · 2021-11-09Clinical Trial Update: Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC [Phase 2]
Phase 2 trial of bemcentinib plus pembrolizumab in triple-negative and inflammatory breast cancer was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa [Phase 2]
A Phase 2 study evaluated paclitaxel plus trastuzumab and pertuzumab as pre-operative therapy for inflammatory breast cancer; the trial is c…
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer [Phase 3]
Phase 3 clinical trial evaluating whether maintenance chemotherapy after induction improves outcomes for inflammatory breast cancer; study c…
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Denosumab as an add-on Neoadjuvant Treatment (GeparX) [Phase 2]
Phase 2 trial update on denosumab added to neoadjuvant therapy for various breast cancer subtypes; study completed.
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy [Phase 3]
Phase 3 trial evaluating adjuvant chemotherapy in breast cancer patients who had partial or complete response to neoadjuvant chemotherapy.
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients [Phase 2]
Phase 2 clinical trial update evaluating efficacy and tolerance of bevacizumab in Her2-negative inflammatory breast cancer.
-
CLINICAL_TRIALS trial_result · 2019-07-17Clinical Trial Update: Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC) [Phase 2]
A Phase 2 trial of nintedanib for HER2-negative metastatic inflammatory breast cancer was terminated with results posted in 2019.